Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

Alexander R. Tamm 1,*, Martin Geyer 1, Felix Kreidel 1, Lea Dausmann 1, Caroline Jablonski 1, Omar Hahad 1,2, Eberhard Schulz 3, Thomas Münzel 1,2 and Ralph Stephan Von Bardeleben 1

1 Department of Cardiology, Cardiology I, University Medical Center Mainz, Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany; martin.geyer@unimedizin-mainz.de (M.G.); felix.kreidel@unimedizin-mainz.de (F.K.); dausmannl@gmail.com (L.D.); cjablons@students.uni-mainz.de (C.J.); omahahad@unimedizin-mainz.de (O.H.); t.muenzel@uni-mainz.de (T.M.); stephan.von_bardeleben@unimedizin-mainz.de (R.S.V.B.)
2 German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, 55131 Mainz, Germany
3 Department of Cardiology, Hospital Celle, Siemensplatz 4, 29223 Celle, Germany; eberhard.schulz@akh-celle.de
* Correspondence: alexander.tamm@unimedizin-mainz.de; Tel.: +49-(0)6131-17-7250

Abstract: The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up: 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prostheses mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p < 0.001), there was a trend to less paravalvular regurgitation (PVR moderate or severe: 1% vs. 3.6%, p = 0.088). All-cause mortality up to 5 years did not show a difference (mean survival S3 3.5 ± 0.24 years, ER 3.3 ± 0.29 years, p = 0.895). Independent predictors of long-term mortality were impaired LVEF, chronic kidney injury, peripheral artery disease, malignant tumor and periprocedural stroke. New generation TAVR valves offer an excellent implant and outcome success rate. Long-term survival was independent of prostheses choice and mainly attributed to comorbidities and complications.

Keywords: aortic valve stenosis; TAVR; long-term outcomes; new-generation trans-catheter heart valves

1. Introduction

Since the first transcatheter aortic valve replacement (TAVR) in 2002 [1] percutaneous therapy of aortic valve stenosis (AS) has evolved rapidly. Today, TAVR is the first option for older patients with AS at intermediate or high risk for surgery [2,3]. Constant development of bioprosthetic valves and delivery systems have reduced complication rates and improved outcomes over the years [4–7]. The 3rd generation Edwards SAPIEN 3 Valve (S3, Edwards Lifesciences Inc., Irvine, CA, USA) and the 2nd generation Medtronic Evolut R Valve (ER, Medtronic Inc. Minneapolis, MN, USA) are the most frequently used prostheses worldwide. There is a paucity of published data regarding long term outcomes in these new generation prostheses TAVR patients. We therefore present a single center analysis of TAVR with S3 and ER valves in comparison with focus on long-term follow up.

2. Materials and Methods

Between June 2014 and May 2016, 489 consecutive patients underwent TAVR in the Heart Valve Center Mainz, Germany. We included 359 patients with severe degenerative
aortic valve stenosis treated via transfemoral access using a new generation prosthesis (S3 or ER) in the study. Exclusion criteria were transapical access, valve-in-valve-procedure or the use of a non-ER or -S3 prosthesis type (Figure 1). The assignment to one of the valve platforms was chosen by the interventionalist regarding individual patient factors, which included calcification of the cusps, annulus and left ventricular outflow tract as well as possible need for future coronary intervention or beneficial femoral access. The TAVR procedure was performed according to the former standard protocol for transfemoral access that included general anesthesia and cross over safety technique. Pre- and post-dilatation were performed at the discretion of the interventionalist. The antithrombotic and antiplatelet regimen was standardized to lifetime Aspirin (or Warfarin in case of need for anticoagulation) and addition of Clopidogrel for 6 months.

![Figure 1](Image)

**Figure 1.** Patient Population. A total of 489 patients undergoing TAVR were screened for the analysis. Reasons for exclusion are displayed in the red box. TAVR = transcatheter aortic valve replacement; TF = transfemoral; AS = aortic stenosis; DFM = Direct Flow Medical.

Patient characteristics, imaging and procedural parameters were retrospectively recorded in a Microsoft Excel database (Microsoft Corporation, Redmond, WA, USA). The peri- and post-procedural outcomes of these patients were analyzed according to the updated criteria of the Valve Academic Research Consortium (VARC-2) [8]. In addition, VARC-2 composite end points of device success and early safety were calculated. The extent of calcification of the aortic valve commissures and annulus or LVOT was determined using separate four-step visual scales according to Marwan et al., and mean value was reported [9].

A follow-up on mortality status until August 2019 could be achieved in 92% of the patients through state civil registries and our University outpatient department. The study was approved by the local ethics committee (number 2019-14692).

All data is described as absolute numbers and percentage in case of nominal variables, as well as mean with standard deviation in case of metrical variables. Differences between patient groups were tested by Chi-squared test and Student’s t-test for nominal and metrical variables, respectively, if normally distributed, and with Mann-Whitney-U-Test if not normally distributed. Kaplan-Meier survival analysis was used for time dependent all-cause mortality. Comparison of the different groups was carried out with Cox proportional hazard models and Log-rank test. All analyses were performed with IBM SPSS Statistics version 24 (IBM Corporation, New York, NY, USA) and GraphPad PRISM version 8 (GraphPad Software, LLC., San Diego, CA, USA).
3. Results

The study population consisted of 359 patients with severe aortic stenosis who underwent transfemoral TAVR with a new generation prosthesis. The median follow-up period was 3.8 years (IQR 3.3 to 4.4 years, maximum follow-up in living patients 5.1 years). The SAPIEN 3 group included 215 patients, the Evolut R group 144 patients.

Baseline patient characteristics are displayed in Table 1. The mean patient age was 82 ± 7 years and 47% were men. The mean EuroSCORE II was 8.0 ± 8%; the mean STS Score PROM was 7.3 ± 9%. More patients in the S3 group were men (55% vs. 34%, p < 0.001), had a history of myocardial infarction (21% vs. 13%, p = 0.05) and were suffering from hypertension (92% vs. 82%, p = 0.006). S3 patients also had a lower mean left ventricular ejection fraction (50% vs. 55%, p < 0.001). In the ER group the prevalence of diabetes (28% vs. 38%, p = 0.041) and pulmonary hypertension (19% vs. 28%, p = 0.041) was higher, additionally these patients had a smaller calculated aortic valve area (0.8 cm² vs. 0.7 cm², p = 0.017).

Table 1. Baseline Patient Characteristics.

| Characteristic                              | All Patients (n = 359) | SAPIEN 3 (n = 215) | Evolut R (n = 144) | p-Value |
|---------------------------------------------|------------------------|--------------------|--------------------|---------|
| Age (Years)                                 | 81.9 ± 6.6             | 81.7 ± 6.6         | 82.2 ± 6.7         | 0.469   |
| Male Sex-%                                  | 167 (46.5)             | 118 (54.9)         | 49 (34)            | <0.001  |
| BMI (kg/m²)                                 | 27.1 ± 5.4             | 27.2 ± 5.2         | 27 ± 5.8           | 0.773   |
| EuroSCORE II                                | 8.0 ± 8.1              | 8.2 ± 8.2          | 7.8 ± 8.1          | 0.621   |
| STS Score PROM                               | 7.3 ± 8.9              | 7.3 ± 6.8          | 7.4 ± 5.0          | 0.092   |
| NYHA Class ≥ III-%                          | 259 (72.1)             | 149 (69.3)         | 110 (76.4)         | 0.142   |
| Coronary Artery Disease-%                   | 224 (62.4)             | 137 (63.7)         | 87 (60.4)          | 0.526   |
| Previous Myocardial Infarction-%            | 62 (17.3)              | 44 (20.5)          | 18 (12.5)          | 0.05    |
| Previous PCI-%                              | 140 (39)               | 89 (41.4)          | 51 (35.4)          | 0.255   |
| Previous CABG-%                             | 45 (12.5)              | 28 (13.0)          | 17 (11.8)          | 0.733   |
| Previous Stroke or TIA-%                    | 60 (16.7)              | 42 (19.5)          | 18 (12.5)          | 0.08    |
| Peripheral Art. Disease ≥ Grade II          | 33 (9.2)               | 17 (7.9)           | 16 (11.1)          | 0.303   |
| Art. Hypertension-%                         | 314 (87.5)             | 196 (91.6)         | 118 (81.9)         | 0.006   |
| Diabetes (%)                                | 114 (31.7)             | 59 (27.9)          | 55 (38.2)          | 0.041   |
| COPD ≥ Grade II (GOLD)-%                   | 37 (10.3)              | 23 (10.7)          | 14 (9.7)           | 0.766   |
| GFR < 30 ml/min                             | 62 (17.3)              | 34 (15.8)          | 28 (19.4)          | 0.372   |
| History of Cancer                           | 45 (12.5)              | 26 (12.1)          | 19 (13.2)          | 0.757   |
| Atrial Fibrillation-%                       | 87 (24.2)              | 55 (25.9)          | 32 (22.4)          | 0.66    |
| Permanent Pacemaker/ICD-%                   | 41 (11.4)              | 25 (11.6)          | 16 (11.1)          | 0.88    |
| Pulm. Hypertension-%                        | 80 (22.3)              | 40 (18.6)          | 40 (27.8)          | 0.041   |
| Left Ventricular Ejection Fraction (%)      | 51.5 ± 13.5            | 49.6 ± 14.4        | 54.5 ± 11.3        | <0.001  |
| Aortic Valve Area (cm²)                     | 0.74 ± 0.2             | 0.80 ± 0.2         | 0.71 ± 0.2         | 0.017   |
| Aortic Valve Peak Gradient (mmHg)           | 68.4 ± 25.7            | 67.5 ± 25.5        | 69.9 ± 26          | 0.367   |
| Aortic Valve Mean Gradient (mmHg)           | 40.4 ± 16.8            | 39.9 ± 16.4        | 41.2 ± 17.2        | 0.493   |
| Commissural Calcification (mean)            | 1.80 ± 0.7             | 1.80 ± 0.8         | 1.81 ± 0.7         | 0.941   |
| Annular/LVOT Calcification (mean)           | 0.77 ± 0.9             | 0.70 ± 0.9         | 0.88 ± 1.0         | 0.077   |

BMI = Body Mass Index, EuroSCORE = European System for Cardiac Operative Risk Evaluation, STS = Society of Thoracic Surgeons, PROM = predicted risk of mortality, NYHA class = New York Heart Association Functional Classification of Heart Failure, PCI = Percutaneous Coronary Intervention, CAGB = Coronary Artery Bypass Graft, TIA = Transient Ischemic Attack, COPD = Chronic Obstructive Pulmonary Disease, GFR = Glomerular filtration rate, ICD = Internal Cardioverter Defibrillator.

Choice of prosthesis size differed significantly between both groups (Table 2). Whereas size distribution in the S3 group was balanced, in the ER group the 29 mm prosthesis was mainly implanted (76.4% of ER implantations). Balloon Pre-Dilatation was about equal in both groups (84.2% vs. 85.4%, p = 0.674), but need for post-dilatation was substantially higher in ER patients (0.5% vs. 18.8%, p < 0.001). Fluoroscopy time and volume of contrast did not differ between both groups.

Peri- and post-procedural outcome parameters are shown in Table 3. Device Success rates (VARC-2 composite endpoint) were about equal in both groups (93.0% vs. 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group and 2.1% in the ER group, respectively (p = 0.674). There was no difference in stroke rate, conversion to open heart surgery, major vascular complications, life-threatening or disabling bleeding or myocardial infarction. The VARC-2 composite endpoint of Early Safety at 30 days also did not differ...
significantly between both groups (11.2% vs. 7.6%, \( p = 0.270 \)). Patients in the S3 group had a higher incidence of periprocedural acute kidney injury which did not reach statistical significance (2.3% vs. 0%, \( p = 0.065 \)).

### Table 2. Procedural Details.

| Prosthesis Size | SAPIEN 3 (\( n = 215 \)) | Evolut R (\( n = 144 \)) | \( p \)-Value |
|-----------------|--------------------------|--------------------------|--------------|
| 23 mm-n (%)     | 83 (38.6)                | 2 (1.4)                  | <0.001       |
| 26 mm-n (%)     | 91 (42.3)                | 32 (22.2)                |              |
| 29 mm-n (%)     | 41 (19.1)                | 110 (76.4)               |              |
| Balloon Pre-Dilatation | 181 (84.2)             | 123 (85.4)               | 0.751        |
| Balloon Post-Dilatation | 1 (0.5)                | 27 (18.8)                | <0.001       |
| Fluoroscopy Time (min) | 25.4 ± 11.4             | 24.5 ± 10.2              | 0.776        |
| Contrast Volume (cc) | 172.1 ± 61.1            | 157.5 ± 56.4             | 0.454        |

### Table 3. Peri- and Post-procedural Outcome.

| All Patients (\( n = 359 \)) | SAPIEN 3 (\( n = 215 \)) | Evolut R (\( n = 144 \)) | \( p \)-Value |
|-------------------------------|--------------------------|--------------------------|--------------|
| 30-Day Mortality              | 9 (2.5)                  | 6 (2.8)                  | 3 (2.1)      | 0.674       |
| VARC-2 Device Success-n (%)   | 333 (92.8)               | 200 (93.0)               | 133 (92.4)   | 0.812       |
| VARC-2 Early Safety at 30 days-n (%) | 35 (9.7)          | 24 (11.2)                | 11 (7.6)     | 0.27        |
| Conversion to Open Heart Surgery | 3 (0.8)                | 2 (0.9)                  | 1 (0.7)      | 0.810       |
| Stroke-n (%)                  | 8 (2.2)                  | 6 (2.8)                  | 2 (1.4)      | 0.378       |
| Major Vascular Complication-n (%) | 14 (3.9)              | 7 (3.3)                  | 7 (4.9)      | 0.441       |
| Life-Threatening or Disabling Bleeding-n (%) | 6 (1.7)             | 4 (1.9)                  | 2 (1.4)      | 0.733       |
| Myocardial infarct-n (%)      | 1 (0.3)                  | 1 (0.5)                  | 0            | 0.412       |
| Acute Kidney Injury ≥ 2-n (%) | 5 (1.4)                  | 5 (2.3)                  | 0            | 0.065       |
| Permanent Pacemaker Implantation-n (%) | 109/318 (34.3)      | 52/190 (27.4)            | 57/128 (44.5) | 0.002       |
| Prosthesis Mean Gradient (mmHg) | 10.5 ± 5.0             | 12.0 ± 4.4               | 8.2 ± 5.1    | <0.001      |
| Paravalvular Regurgitation ≥ 2-n (%) | 7/348 (1.9)          | 2/209 (1.0)              | 5/139 (3.6)  | 0.088       |

VARC-2 = Valve Academic Research Consortium Updated Standardized Endpoint Definitions, Explanation of Composite Endpoints: Device Success = absence of procedural mortality, correct positioning of a single prosthetic heart valve and intended performance of prosthetic valve. Early Safety at 30 days = all-cause mortality, stroke, life-threatening bleeding, acute kidney injury ≥ 2, coronary artery obstruction requiring intervention, major vascular complication, valve-related dysfunction requiring repeat procedure.

Implantation of a new permanent pacemaker (PPI) was lower in the S3 group (27.4% vs. 44.5%, \( p = 0.002 \)). While prosthesis mean gradients were higher in the S3 group (12.0 mmHg vs. 8.2 mmHg, \( p < 0.001 \)), there was a tendency to less paravalvular leaks (PVL ≥ 2: 1% vs. 3.6%, \( p = 0.088 \)). Furthermore, there was early improvement of Left Ventricular Ejection Fraction, Mitral Regurgitation and Systolic Pulmonary Pressures at 30 days, which showed consistent values at one year follow up (Supplement Table S1).

Recorded overall all-cause mortality was 16.3% at 1 year, 27.3% at 2 years and 37.5% at 3 years. Estimated mortality by Kaplan-Meier analysis (Figure 2) did not show a difference between both patient groups in long-term follow-up (mean survival S3 3.5 years, ER 3.3 years, \( p = 0.895 \)). Subgroup analysis demonstrated a survival benefit for S3 patients with peripheral disease (HR for mortality ER vs. S3: 2.887, \( p = 0.018 \)) or history of stroke (HR 3.599, \( p = 0.001 \)). Additionally, male patients seemed to benefit from S3 (HR 1.498, \( p = 0.104 \)) and female patients from ER implantation (HR 0.721, \( p = 0.149 \)), although both did not reach statistical significance (Figure 3).

Univariate analysis (Supplement Table S2) showed a correlation between death of any cause and LVEF ≤ 50% (HR 1.65, \( p = 0.001 \)), peripheral artery disease (HR 1.81, \( p = 0.011 \)), chronic kidney injury (HR 1.49, \( p = 0.027 \)) and history of cancer (HR 2.03, \( p < 0.001 \)). In multivariate analysis (Supplement Table S2) independent predictors of all-cause mortality were LVEF ≤ 50% (HR 1.65, \( p = 0.005 \)), peripheral artery disease (HR 2.30, \( p = 0.001 \)), chronic kidney injury (HR 1.52, \( p = 0.042 \)), COPD (HR 1.70, \( p = 0.043 \)), history of cancer (HR 2.45, \( p < 0.001 \)) and periprocedural stroke (HR 4.22, \( p = 0.007 \)). However, the type of prosthesis was no predictor of mortality (HR 0.94, \( p = 0.732 \)).
prosthesis was no predictor of mortality (HR 0.94, p = 0.732).

Figure 2. All-Cause Mortality. Kaplan-Meier Estimator of Death from any cause according to prosthesis type up to 5 years of follow-up. Edwards SAPIEN 3 (blue line); Medtronic Evolut R (red line).

| Subgroup | Hazard Ratio (95% CI) | Favors Evolut R < > Favors Sapien 3 | p value |
|----------|----------------------|-------------------------------------|---------|
| Sex      |                      |                                     |         |
| Female   | 0.721 (0.462 - 1.125) |                                     | 0.149   |
| Male     | 1.498 (0.920 - 2.439) |                                     | 0.104   |
| Age      |                      |                                     |         |
| < 80 years | 0.748 (0.434 - 1.290) |                                     | 0.526   |
| ≥ 80 years | 1.141 (0.758 - 1.718) |                                     | 0.296   |
| Diabetes |                      |                                     |         |
| Yes      | 0.908 (0.525 - 1.570) |                                     | 0.729   |
| No       | 0.977 (0.648 - 1.474) |                                     | 0.912   |
| Stroke   |                      |                                     |         |
| Yes      | 3.599 (1.652 - 7.843) |                                     | 0.001   |
| No       | 0.756 (0.526 - 1.087) |                                     | 0.131   |
| CAD      |                      |                                     |         |
| Yes      | 0.951 (0.630 - 1.437) |                                     | 0.813   |
| No       | 0.989 (0.578 - 1.692) |                                     | 0.957   |
| PAD      |                      |                                     |         |
| Yes      | 2.887 (1.195 - 6.973) |                                     | 0.018   |
| No       | 0.830 (0.573 - 1.174) |                                     | 0.279   |
| LVEF ≤ 50% | 1.065 (0.691 - 1.643) |                                     | 0.374   |
| > 50%    | 1.134 (0.699 - 2.039) |                                     | 0.516   |
| CKD Grade 3/4 | 1.387 (0.727 - 2.646) |                                     | 0.320   |
| No       | 0.847 (0.579 - 1.238) |                                     | 0.390   |
| COPD     |                      |                                     |         |
| Yes      | 0.466 (0.167 - 1.298) |                                     | 0.144   |
| No       | 1.056 (0.747 - 1.494) |                                     | 0.758   |

Figure 3. Prosthesis Choice. Subgroup Analysis by Cox Regression according to Prosthesis Choice. Stroke = History of Stroke, CAD = Coronary Artery Disease, PAD = Peripheral Artery Disease, CKD = Chronic Kidney Disease, LVEF = Left Ejection Fraction, COPD = Chronic Pulmonary Disease.

4. Discussion

With this study we present a comparison of the new-generation aortic valve prostheses Edwards SAPIEN 3 and Medtronic Evolut R concerning long-term as well as peri- and post-procedural outcomes. The analyzed cohort consisted of patients at intermediate to high surgical risk expressed through a EuroSCORE II of 8.0% and STS Score of 7.3% in mean, respectively. Device success in both groups was comparably good and is in line with previous studies using VARC-2 definitions [10,11]. Although ER patients needed significantly more post-dilatation after TAVR, fluoroscopy times and contrast use were about equal between both groups. These findings are supported by the literature and are constant with older and new generation valves [10,12].

Regarding periprocedural outcomes, both prostheses showed similar favorable results with very low incidences of stroke, vascular or bleeding complications as well as myocardial infarction or conversion to open heart surgery. Nevertheless, acute kidney
injury stage 2 or higher was tendentially more often recorded in the S3 group. Finkelstein et al. describe similar observations, while other studies do not see differences between both prostheses [10,13,14]. Additionally, patients in the ER group had lower prosthetic mean gradients in the follow up echocardiography, which is a common finding in the literature [10,13]. An explanation should be the supra-annular design of the Evolut R platform as well as the bigger number of smaller prostheses in the S3 group (38.6% use of the 23 mm valve).

In general, we could show a very low incidence of relevant paravalvular regurgitation (moderate or severe PVL 1.9%), a complication that has been associated with worse long-term survival before [15]. These findings are comparable to the reported rates of moderate or severe PVL with new generation prostheses in the literature (S3 1.4–3.1%, ER 1.9–4.0%) [11,13,16,17]. Nevertheless, there was a tendency to less PVL in the S3 group (S3 1.0%, ER 3.6%, p = 0.088) which can be related to the newly developed outer skirt on the SAPIEN 3 prosthesis. Another confounder could be a selection tendency towards ER in very calcified annuli/LVOT that would lead to worse sealing. A further development of the Evolut platform with an added sealing skirt was not available at the time of patient inclusion (Evolut Pro, CE-Mark 2017).

The numbers of postinterventional need for permanent pacemaker seem high in comparison to similar studies (S3: 7.8–24.0%, ER: 16.4–25.0%), which could be explained by a low threshold for implantation in our institution at that time (including persisting left bundle branch block with AV-Block I or bradyarrhythmia). However, the difference between both groups in favor of SAPIEN 3 (ER patients had 1.6-fold higher PPI rates compared to S3 patients) is comparable to the literature [10,11,16,18–20].

Despite treating a population at substantially increased risk, the 30-day mortality was very low at 2.5% overall with no relevant difference between both groups. Previous studies show comparable mortality data (S3: 0–3.1%, ER 1.9–3.4%) with transfemoral TAVR patients at lower to similar risk profile (EuroSCORE II 5.2–6.1%, STS Score 4.3–7.7%) [10,11,16,18–20].

Regarding survival there was no difference between S3 and ER patients with a mean survival of 3.5 and 3.3 years, respectively. This finding could also be confirmed in multivariate analysis (HR 0.937, p = 0.732). A recent work by Finkelstein et al. presented data with the same prostheses in low-risk patients showing similar mortality between both groups up to 3 years [13]. Vollenbroich et al. who studied long-term outcomes with the older platforms Edwards SAPIEN THV/XT and Medtronic CoreValve in a similar risk cohort could also show comparable all-cause mortality at 5 years between both patient groups (53.4% vs. 46.9%, p = 0.15) [21].

As in most studies concerning TAVR, long-term survival was mainly attributed to comorbidities such as reduced LVEF, peripheral artery disease, chronic kidney injury, advanced COPD or history of cancer. In addition, periprocedural stroke was the most important independent predictor of all-cause mortality up to five years. This finding is supported by a work from Levi et al. that showed a similar relevance of in-hospital stroke for long-term survival [22].

Limitations of the Study

The present study has to be interpreted with regard to several limitations. First, it is a retrospective analysis that has inherent limitations and is open to bias. Second, the study was conducted at a single center, thus results might not be generally applicable. Third, the choice of the platform was not randomized but up to the decision of the implanter which could result in biased periprocedural outcome parameters. Since 34 mm ER was not on the market in the reported inclusion time, there might be a bias towards treating more patients with larger annuli with the S3 29 mm valve, which could explain the higher number of male patients treated in the SAPIEN group. At 5 years after implantation the number of patients that are included in the follow-up is low, thus the median follow-up time of 3.8 years could also be addressed as intermediate- to long-term follow-up.
5. Conclusions

Transcatheter aortic valve replacement (TAVR) has become a standard therapy in treating AS. Published data regarding long-term outcomes in patients with new generation TAVR prostheses (Edwards SAPIEN 3 Valve, Medtronic Evolut R Valve) are scarce. We therefore present a large single center analysis of TAVR with SAPIEN 3 and Evolut R valves in comparison with focus on long-term follow up. Our single-center cohort data adds an industry-independent comparison between new-generation valves concerning periprocedural outcomes and long-term survival in a routine TAVR cohort. We demonstrated low procedural mortality and low paravalvular leakage rates in new generation TAVR. Mid- to long-term follow-up shows favorable similar survival in both prosthesis groups.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10143102/s1, Table S1: Echocardiographic Parameters; Table S2: Predictors of All-Cause Mortality.

Author Contributions: Conceptualization, A.R.T and E.S.; methodology, M.G., L.D., C.J. and O.H.; formal analysis, A.R.T., F.K. and O.H.; investigation, M.G., F.K., O.H. and E.S.; data curation, L.D. and C.J.; writing—original draft preparation, A.R.T.; writing—review and editing, A.R.T., M.G. and R.S.V.B.; visualization, A.R.T.; supervision, E.S., T.M. and R.S.V.B.; project administration, A.R.T., T.M. and R.S.V.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the University Medical Center Mainz, Germany (reference number: 2019-14692).

Informed Consent Statement: All patients provided written consent.

Data Availability Statement: The datasets generated for this study are available on request to the corresponding author.

Acknowledgments: This work contains part of the theses of Lea Dausmann and Caroline Jablonski.

Conflicts of Interest: A.R.T. reports having received lecture honoraria from Edwards Lifesc. and Medtronic Inc.; F.K. reports having received consultancy and lecture honoraria from Abbott Lab. and Edwards Lifesc.; E.S. reports having received lecture honoraria from Edwards Lifesc. and Medtronic Inc.; R.S.V.B. reports having received consultancy and lecture honoraria from Abbott Lab. and Edwards Lifesc.; the other authors have no conflict of interest to declare.

References

1. Cribier, A.; Eltchaninoff, H.; Bash, A.; Borenstein, N.; Tron, C.; Bauer, F.; Derumeaux, G.; Anselme, F.; Laborde, F.; Leon, M.B. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: First human case description. *Circulation* **2002**, *106*, 3006–3008. [CrossRef]

2. Baumgartner, H.; Falk, V.; Bax, J.J.; De Bonis, M.; Hamm, C.; Holm, P.J.; Jung, B.; Lancellotti, P.; Lansac, E.; Rodriguez Munoz, D.; et al. ESC/EACTS guidelines for the management of valvular heart disease. *Eur. Heart J.* **2017**, *38*, 2739–2791. [CrossRef] [PubMed]

3. Nishimura, R.A.; Otto, C.M.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P.; 3rd Fleisher, L.A.; Jneid, H.; Mack, M.J.; McLeod, C.J.; O’Gara, P.T.; et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. *Circulation* **2017**, *135*, e1159. [CrossRef] [PubMed]

4. Adams, D.H.; Popma, J.J.; Reardon, M.J.; Yakubov, S.J.; Coselli, J.S.; Deeb, G.M.; Gleason, T.G.; Buchbinder, M.; Hermiller, J., Jr.; Kleiman, N.S.; et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N. Engl. J. Med.* **2014**, *370*, 1790–1798. [CrossRef] [PubMed]

5. Reardon, M.J.; Van Mieghem, N.M.; Popma, J.J.; Kleiman, N.S.; Sondergaard, L.; Mumtaz, M.; Adams, D.H.; Deeb, G.M.; Maini, B.; Gada, H.; et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *N. Engl. J. Med.* **2017**, *376*, 1321–1331. [CrossRef]

6. Leon, M.B.; Smith, C.R.; Mack, M.J.; Makkar, R.R.; Svensson, L.G.; Kodali, S.K.; Thourani, V.H.; Tuzcu, E.M.; Miller, D.C.; Herrmann, H.C.; et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N. Engl. J. Med.* **2016**, *374*, 1609–1620. [CrossRef] [PubMed]
